OPCON
Clinical safety rating
cautionComprehensive clinical and safety monograph for OPCON (OPCON).
Opcon is a brand name for the injectable solution containing desmopressin acetate, a synthetic analog of the antidiuretic hormone vasopressin. It acts on V2 receptors in the renal collecting ducts to increase water reabsorption, reducing urine volume and osmolality.
| Metabolism | Primarily metabolized in the liver by disulfide bond reduction and peptide cleavage. Not significantly metabolized by cytochrome P450 enzymes. |
| Excretion | Renal elimination of unchanged drug accounts for approximately 65-70% of the administered dose; biliary/fecal excretion accounts for 20-25% following hepatic metabolism. |
| Half-life | The terminal elimination half-life is 8-12 hours in adults with normal renal function. This supports twice-daily dosing; half-life is prolonged in renal impairment. |
| Protein binding | Approximately 80-85% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is approximately 1.5-2.0 L/kg, indicating extensive distribution into total body water and tissues. |
| Bioavailability | Oral bioavailability is 85-90% due to minimal first-pass metabolism; intramuscular bioavailability is nearly 100%. |
| Onset of Action | Intravenous: within 2-3 minutes; oral: 30-60 minutes; intramuscular: 10-15 minutes. |
| Duration of Action | Duration of clinical effect is approximately 6-8 hours for standard doses; may extend to 12 hours in patients with hepatic impairment. |
| Molecular Weight | 180.2 |
IV: 2-4 mg bolus, may repeat every 5-10 minutes as needed; max total dose: 10 mg.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | Child-Pugh Class A and B: No adjustment. Child-Pugh Class C: Use with caution; consider dose reduction by 50%. |
| Pediatric use | IV: 0.02-0.04 mg/kg/dose every 5-10 minutes as needed; max single dose: 0.1 mg/kg; max total dose: 2 mg. |
| Geriatric use | Initiate at lower end of dosing range (e.g., 1-2 mg IV); titrate carefully due to increased sensitivity. |
| 1st trimester | Avoid in first trimester; associated with major congenital malformations including neural tube defects and cardiovascular anomalies. Limited data suggest potential for fetal harm. |
| 2nd trimester | Associated with intracranial hemorrhage and fetal lung hypoplasia when used in second trimester. Use only if clearly needed. |
| 3rd trimester | Risk of premature closure of ductus arteriosus, pulmonary hypertension, and oligohydramnios. Contraindicated after 30 weeks gestation. |
Clinical note
Comprehensive clinical and safety monograph for OPCON (OPCON).
| Placental transfer | Readily crosses placenta; fetal levels 50-70% of maternal levels. Extensive placental transfer documented. |
| Breastfeeding | Excreted into breast milk; may cause neonatal hypoglycemia, hyperbilirubinemia, and kernicterus. Avoid breastfeeding or use alternative therapy. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | Pregnancy Category C. First trimester: potential risk of congenital anomalies based on animal data; second and third trimesters: risk of fetal hypoxia and bradycardia due to uterine hypertonus. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and uterine activity. Fetal heart rate monitoring during administration. Assess for signs of uterine hyperstimulation. |
| Fertility Effects | May cause endometrial changes and alter ovarian function. Limited data suggest possible transient effects on ovulation and implantation. |
■ FDA Black Box Warning
WARNING: SEVERE HYPONATREMIA. Desmopressin can cause hyponatremia which may be life-threatening if severe and untreated. Risk is increased in patients with conditions predisposing to hyponatremia or those receiving certain medications. Monitor serum sodium levels, especially in the elderly, children, and patients with increased intracranial pressure.
| Serious Effects |
Hypersensitivity to OPCON or any componentActive peptic ulcer diseaseHistory of aspirin-exacerbated respiratory diseaseHemophilia or bleeding disordersSevere hepatic impairmentPreterm labor (tocolysis with OPCON is not recommended)
| Precautions | Risk of severe hyponatremia and seizures; monitor fluid intake and serum sodium; use with caution in patients with fluid and electrolyte imbalances, renal impairment, cystic fibrosis, coronary artery disease, hypertension, and in the elderly; may increase blood pressure; avoid in patients with nephrotic syndrome or nephropathy; use with caution in patients receiving drugs that increase diuresis or thirst. |
| Food/Dietary | No specific food interactions. Avoid alcohol as it may increase dizziness or drowsiness. |
| Clinical Pearls | OPCON is a brand name for oxymetazoline, an α-adrenergic agonist used topically for nasal congestion. Avoid use beyond 3 days to prevent rhinitis medicamentosa. Contraindicated in narrow-angle glaucoma and after transsphenoidal hypophysectomy. Monitor for rebound congestion. |
| Patient Advice | Do not use for more than 3 days to avoid worsening congestion. · Spray once into each nostril twice daily as needed. · Avoid contact with eyes; rinse with water if contact occurs. · Do not share the bottle to prevent infection. · Consult a doctor if symptoms persist beyond 3 days. |
Loading safety data…